Literature DB >> 6943823

Parafoveal retinal telangiectasis. Light and electron microscopy studies.

W R Green, H A Quigley, Z De la Cruz, B Cohen.   

Abstract

The clinical, histopathological, and ultrastructural features of a case of parafoveal telangiectasis are reported. No telangiectasis of retinal vessels was found. Instead, there was thickening of the wall of the retinal capillaries and narrowing of the calibre of the lumen. Thickening was due to marked proliferation of basement membrane in a multilayered configuration, Cellular debris from degenerated endothelial cells and pericytes, and multimembranous lamellar lipid material were entrapped between layers of basement membrane. Extensive degeneration of pericytes was observed, and occasional areas showed degenerated endothelial cells. These changes were not restricted to the clinical-affected parafoveal area but were also seen to a lesser degree throughout the retina. The changes are interpreted as being due to primary endothelial cell degeneration and regeneration, with successive waves of basement membrane production and secondary degeneration of pericytes.

Entities:  

Mesh:

Year:  1980        PMID: 6943823

Source DB:  PubMed          Journal:  Trans Ophthalmol Soc U K        ISSN: 0078-5334


  26 in total

1.  Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial.

Authors:  Brian C Toy; Euna Koo; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

2.  Macular edema associated with latanoprost use in a patient with idiopathic juxtafoveal retinal telangiectasis.

Authors:  Tetsuya Baba; Mikio Nagayama; Hiroshi Ohtsuki; Kazuyuki Hirooka; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2008-03-28       Impact factor: 2.447

3.  Basement membrane changes in capillaries of the ageing human retina.

Authors:  Michael B Powner; Andrew Scott; Meidong Zhu; Peter M G Munro; Alexander J E Foss; Gregory S Hageman; Mark C Gillies; Marcus Fruttiger
Journal:  Br J Ophthalmol       Date:  2011-05-23       Impact factor: 4.638

4.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2.

Authors:  Michael B Powner; Mark C Gillies; Marina Tretiach; Andrew Scott; Robyn H Guymer; Gregory S Hageman; Marcus Fruttiger
Journal:  Ophthalmology       Date:  2010-08-03       Impact factor: 12.079

5.  Demographic features of idiopathic macular telangiectasia in Japanese patients.

Authors:  Ichiro Maruko; Tomohiro Iida; Yukinori Sugano; Akira Ojima; Hiroshi Oyamada; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2012-01-06       Impact factor: 2.447

6.  The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia.

Authors:  Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-29       Impact factor: 4.799

7.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 8.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

9.  Intravitreal injection of fibroblasts: the pathological effects on the ocular tissues of the rabbit following an intravitreal injection of autologous skin fibroblasts.

Authors:  C A Hitchins; I Grierson
Journal:  Br J Ophthalmol       Date:  1988-07       Impact factor: 4.638

10.  Retinal and choroidal ischemic syndrome, digestive tract and renal small vessel hyalinosis, intracerebral calcifications and phenotypic abnormalities: a new family syndrome.

Authors:  G van Effenterre; J Haut; A Brezin; Y Le Mer; J C Rambaud; A Galian; G Touchard; E Rothschild
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.